Search results for "philia"

showing 10 items of 299 documents

Acquired Hemophilia A Associated with Venous Thrombosis and Very High Inhibitor Titer: A Challenging Scenario

2019

medicine.medical_specialtyVenous thrombosisbusiness.industryInternal medicineAcquired hemophiliaAcquired haemophilia high inhibitor venous thrombosisMedicineGeneral MedicinebusinessBypassing agentmedicine.diseaseGastroenterologyAnnals of Hematology & Oncology
researchProduct

The WFH Haemophilia Centre Twinning Programme: 10 years of growth, 1993-2003

2003

The World Federation of Haemophilia (WFH) Twinning Programme celebrates its tenth anniversary this year. Twinning is one of several international WFH programmes designed to improve haemophilia care at a global level. There are two types of twinning, and the haemophilia treatment centre twinning programme should be distinguished from the WFH haemophilia organization twinning involving national member organizations. The WFH Haemophilia Treatment Centre Twinning Programme helps emerging haemophilia treatment centres develop partnerships with well-established and experienced centres. Twinning can improve diagnosis and clinical care through coaching, training and transfer of expertise, ultimatel…

medicine.medical_specialtybusiness.industryDeveloping countryHematologyGeneral MedicineHaemophiliamedicine.diseaseCoachingQuality of life (healthcare)Family medicineDonationmedicineClinical carebusinessEmerging marketsDeveloped countryGenetics (clinical)Haemophilia
researchProduct

Daptomycin-induced eosinophilic pneumonia: Are there any risk factors?

2020

Abstract Objectives Daptomycin is a widely used antibiotic. Rhabdomyolysis related to daptomycin is one of the adverse effects of treatment, justifying the need for regular monitoring of muscle enzymes throughout treatment. Daptomycin may also lead to eosinophilic pneumonia. However, risk factors for this adverse reaction have not been identified and do not permit targeting of at-risk populations who could benefit from appropriate monitoring. Patients and methods Literature was reviewed for cases of daptomycin-induced eosinophilic pneumonia (DIEP), which that were compared to cases of patients without this adverse effect. Results Fifty patients with DIEP and 54 controls were identified. Age…

medicine.medical_specialtybusiness.industryDiseasemedicine.diseaseAnti-Bacterial AgentsInfectious DiseasesDaptomycinRisk FactorsInternal medicineDiabetes mellitusmedicineEosinophilic pneumoniaHumansDaptomycinRisk factorPulmonary EosinophiliaAdverse effectbusinessRhabdomyolysisPulmonary EosinophiliaLungmedicine.drugInfectious diseases now
researchProduct

Prognostic Parameters For Remission Of and Survival In Acquired Hemophilia A: Results Of The GTH-AH 01/2010 Multicenter Study

2013

Abstract Acquired hemophilia A (AHA) is a rare autoimmune disorder caused by neutralizing autoantibodies against coagulation factor VIII (FVIII:C). Immunosuppressive treatment may result in remission of disease over a period of days to months. Until remission, patients are at high risk of bleeding and complications from immunosuppression. Prognostic parameters to predict remission and the time needed to achieve remission could be helpful to guide treatment intensity, but have not been established so far. GTH-AH01/2010 was a prospective multicenter cohort study using a standardized immunosuppressive treatment protocol. The primary study endpoint was time to achieve partial remission (PR, def…

medicine.medical_specialtybusiness.industryImmunologyComplete remissionCell BiologyHematologyOff-label useBiochemistryHemophiliasInterquartile rangeInternal medicineImmunologyAcquired hemophiliamedicineHemotherapyRituximabbusinessCohort studymedicine.drugBlood
researchProduct

Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01/2010 study

2015

Acquired hemophilia A (AHA) is caused by autoantibodies against factor VIII (FVIII). Immunosuppressive treatment (IST) results in remission of disease in 60% to 80% of patients over a period of days to months. IST is associated with frequent adverse events, including infections as a leading cause of death. Predictors of time to remission could help guide IST intensity but have not been established. We analyzed prognostic factors in 102 prospectively enrolled patients treated with a uniform IST protocol. Partial remission (PR; defined as no active bleeding, FVIII restored >50 IU/dL, hemostatic treatment stopped >24 hours) was achieved by 83% of patients after a median of 31 days (range 7-362…

medicine.medical_specialtybusiness.industryImmunologyHazard ratioAutoantibodyCell BiologyHematologyOdds ratioBiochemistryGastroenterologyConfidence intervalSurgeryhemic and lymphatic diseasesInternal medicinemedicineAcquired hemophiliaAdverse effectbusinessSurvival analysisCause of deathBlood
researchProduct

Joint damage and motor learning during unipedal stance in haemophilia arthropathy: report of two cases

2016

medicine.medical_specialtybusiness.industryMEDLINEHematologyGeneral Medicine030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicinePhysical medicine and rehabilitationGait (human)Joint damagePhysical therapyMedicinebusinessMotor learningHaemophilia arthropathySensorimotor cortex030217 neurology & neurosurgeryGenetics (clinical)
researchProduct

Hemofilia: ejercicio y deporte

2011

El ejercicio físico y el deporte constituyen uno de los pilares básicos en el tratamiento de la hemofilia. Este trabajo describe un resumen de las características de la hemofilia y, a través de una exhaustiva revisión bibliográfica, se analiza la importancia de la condición física, en relación con la prevención y el tratamiento de las lesiones musculoesqueléticas en el paciente hemofílico. La hemofilia es una enfermedad hematológica hereditaria, con lesiones ortopédicas características. Afecta a individuos varones y presenta un déficit de factores de la coagulación que provoca hemorragias incluso espontáneas (en pacientes graves sin tratamiento). Las lesiones más frecuentes son: hemartrosis…

medicine.medical_specialtybusiness.industryPhysical therapyMedicinePhysical Therapy Sports Therapy and RehabilitationOrthopedics and Sports MedicinePhysical exercisebusinessHaemophiliamedicine.diseaseApunts. Medicina de l'Esport
researchProduct

Recombinant FVIII Products (Turoctocog Alfa and Turoctocog Alfa Pegol) Stable Up to 40°C

2021

Mariasanta Napolitano,1 Arne Agerlin Olsen,2 Anne Mette Nøhr,2 Hermann Eichler3 1Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo Reference Regional Center for Thrombosis and Hemostasis, Hematology Unit, Palermo, Italy; 2Novo Nordisk A/S, Biopharm Manufacturing Development, Gentofte, Denmark; 3Saarland University and Saarland University Hospital, Institute of Clinical Haemostaseology and Transfusion Medicine, Homburg (Saar), GermanyCorrespondence: Anne Mette NøhrBiopharm Manufacturing Development, Novo Nordisk A/S, Nybrovej 80, Gentofte 2820, DenmarkTel +45 3075 1619Email amnq@novonordisk.…

medicine.medical_specialtybusiness.industryturoctocog alfa pegolHematologyTuroctocog alfa030204 cardiovascular system & hematologyGastroenterologyJournal of Blood Medicine03 medical and health sciences0302 clinical medicinetemperature stabilityfactor VIII030220 oncology & carcinogenesisAmbient humidityInternal medicinehemic and lymphatic diseasesmedicinePotencyfactor VIII hemophilia A storage flexibility temperature stability turoctocog alfa turoctocog alfa pegolhemophilia Astorage flexibilityturoctocog alfabusinessHot and humidOriginal ResearchJournal of Blood Medicine
researchProduct

Patient preferences in the treatment of hemophilia A: impact of storage conditions on product choice

2018

Bernd Tischer,1 Renato Marino,2 Mariasanta Napolitano3 1Kantar Health, Munich, Germany; 2Haemophilia and Thrombosis Centre, University Hospital of Bari, Apulia, Italy; 3University of Palermo, Reference Regional Center for Thrombosis and Hemostasis Hematology Unit, Palermo, Italy Objectives: To gain insights into the usage of factor VIII (FVIII) products by patients diagnosed with moderate/severe hemophilia A, and to assess the impact and perceived importance of product storage.Methods: In this study, 200 patients diagnosed with moderate or severe hemophilia A across seven countries participated. Data were collected via a 30-minute, face-to-face interview in six countries and via a web-based…

medicine.medical_specialtycongenital hereditary and neonatal diseases and abnormalitieshemophilia A recombinant FVIII plasma-derived FVIII storage reconstitution stabilityTreatment Adherence haemophiliaActivities of daily livingMedicine (miscellaneous)030204 cardiovascular system & hematologySevere hemophilia AHaemophiliaHemophilia Astorage03 medical and health sciences0302 clinical medicinePatient satisfactionrecombinant FVIIIplasma-derived FVIIIhemic and lymphatic diseasesMedicine030212 general & internal medicineProduct (category theory)Pharmacology Toxicology and Pharmaceutics (miscellaneous)Original Researchlcsh:R5-920business.industryHealth Policystabilitymedicine.diseasePatient preferenceConjoint analysisProduct choicePatient Preference and AdherenceEmergency medicinereconstitutionbusinesslcsh:Medicine (General)Social Sciences (miscellaneous)Patient Preference and Adherence
researchProduct

Post-synoviorthesis rehabilitation in haemophilia.

2001

The efficacy of radiosynoviorthesis in the management of chronic haemophilic synovitis has been proven. Like replacement therapy, however, this procedure has no effect on muscle strength or endurance, range of movement, coordination, or the patient's physical condition in general. All the factors just enumerated are essential for the recovery and maintenance of the haemophiliac's quality of life. That is why rehabilitation and physiotherapy are so important, since no medical therapy or surgical procedure are by themselves capable of preventing disabilities.

medicine.medical_specialtymedicine.medical_treatmentRange of movementHaemophiliaHemophilia AQuality of lifeSynovitisHemarthrosismedicineHumansRange of Motion ArticularGenetics (clinical)Physical Therapy ModalitiesRehabilitationSynovitisbusiness.industryHematologyGeneral Medicinemedicine.diseaseMusculoskeletal ManipulationsPractice Guidelines as TopicPhysical therapyMuscle strengthJoint DiseasesRange of motionbusinessMedical therapyMuscle ContractionHaemophilia : the official journal of the World Federation of Hemophilia
researchProduct